Agios Pharmaceuticals Inc

NASDAQ: AGIO

  • Agios Pharmaceuticals Inc
  • Sector

    Health Care
  • Industry

  • Company web

    Link
  • Employees

    Full Time Employees: 287
  • Executives

    • David Schenkein
    • Andrew Hirsch
    • Scott Biller
    • Christopher Bowden
    • Steven Hoerter
    • Lewis Cantley
    • David Scadden
    • Paul Clancy
    • Ian Clark
    • Kaye Foster-Cheek
  • Company address

    • 88 Sidney Street, 2d Floor
    • Cambridge, MA 02139
    • United States of America
    • 1-617-649-8600
  • Investor Relation Site

    Link

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. The company is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients. In addition, it is developing AG-881, a pan-IDH mutant inhibitor that is in Phase 1 clinical trials for the treatment of hematologic malignancies and solid tumors; and AG-348, a small molecule potent activator that is in Phase 2 clinical trial for the treatment of pyruvate kinase deficiency. It has a collaboration and license agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology; and Celgene International II Sarl to develop and commercialize AG-881 products. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Agios Pharmaceuticals Inc: Slide deck


Related companies

Teva Pharmaceutical Industries Limited

Health Care

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic...

Sanofi

Health Care

Sanofi researches, develops, manufactures, and markets therapeutic solutions. The company operates in two segments, Pharmaceuticals and Vaccines. It offers Cerezyme and Cerdelga for Gaucher...

Smith & Nephew SNATS Inc

Health Care

Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array...

Shire plc

Health Care

Shire plc, a biotechnology company, focused on serving people with rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas,...

Koninklijke Philips NV

Health Care

Koninklijke Philips N.V. operates as a health technology company worldwide. It offers diagnostic imaging solutions, magnetic resonance imaging, computed tomography, and diagnostic X-ray; advanced...

Novartis AG

Health Care

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company’s Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for...